Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study

• DOI: 10.3389/fonc.2022.838870
• Publication Date: 2022-03-30T10:56:40Z
• Authors: Donghao Xu; Yu Liu; Wentao Tang; Lingsha Xu; Tianyu Liu; Yudong Jiang; Shizhao Zhou; Xiaorui Qin; Jisheng Li; Jiemin Zhao; Lechi Ye; Wenju Chang; Jianmin Xu
• Keywords: Regorafenib; Refractory (planetary science)

Regorafenib improves progression-free survival (PFS) and overall (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we report the treatment patterns of regorafenib third- or late-line setting for mCRC four centers China.Patients China administered from February 1, 2018 to June 31, 2021 were enrolled. Patients grouped into 3 cohorts, namely, monotherapy (regorafenib alone), chemo plus chemotherapy), immune [regorafenib anti-PD1 (programmed cell death 1) antibodies] groups. Demographic, clinical, safety data retrospectively analyzed.A total 177 included this study. Of them, 116 (65.5%) treated alone, while 28 (15.9%) 33 (18.6%) chemotherapy antibodies, respectively. The median followed-up time was 9.2 months. disease control rate (DCR) 40.7%. PFS (mPFS) 2.43 months OS (mOS) 12.2 group had longer (3.5 m vs. 2.2 m, p = 0.043) compared group. (15.9 8.4 0.032) who began at 120 mg those 80 (PFS: 3.7 2.0 m; <0.001; OS: 13.4 10.2 0.005). a final dose less 5.0 2.3 0.045; UR (unreach) 10.9 0.003). There 87.0% (154/177) experienced AEs. Three groups similar rates AEs (86.2% 89.3% 87.9%; 0.89).Patients alone combination other agents relieved some extent, antibodies showed better PFS, most benefit OS. no significant difference among three terms